MJN110
MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively[1]. MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity[2].
Product Specifications
CAS Number
[1438416-21-7]
UNSPSC
12352005
Hazard Statement
H302
Target
MAGL
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/mjn110.html
Purity
99.83
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)ON4C(CCC4=O)=O
Molecular Formula
C22H21Cl2N3O4
Molecular Weight
462.33
Precautions
H302
References & Citations
[1]Wilkerson JL, et al. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther. 2016 Apr;357 (1) :145-56.|[2]Niphakis MJ, et al. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci. 2013 Sep 18;4 (9) :1322-32.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
243275 100 µg
ALPL (Alkaline Phosphatase, liver/Bone/kidney, AP-TNAP, FLJ40094, FLJ93059, HOPS, MGC161443, MGC167935, TNAP, TNSALP)
Ask
View Details D1660-40D 200 µL
DDX5, CT (Probable ATP-dependent RNA Helicase DDX5, DEAD Box Protein 5, RNA Helicase p68, HLR1, HELR, G17P1, DDX5)
Ask
View Details 
MBS1412625-01 0.02 mg (E-Coli)
Recombinant Moorella thermoacetica UPF0133 protein Moth_0028 (Moth_0028)
Ask
View Details